Background
==========

The meniscus is an important structure of the knee, playing a pivotal role in shock absorption, joint lubrication and nutrition, proprioception, load transmission, joint congruity, and stability \[[@b1-medscimonit-25-8891]\]. A meniscus lesion, predisposing to knee osteoarthritis (OA), is a frequent knee joint injury with high incidence rate, found in 60% of patients with asymptomatic osteoarthritis \[[@b2-medscimonit-25-8891]--[@b4-medscimonit-25-8891]\]. There is a high interdependency between degenerative meniscal lesions (DMLs) and knee OA \[[@b5-medscimonit-25-8891],[@b6-medscimonit-25-8891]\]. DMLs can be a feature of knee OA and are conducive to joint space narrowing \[[@b7-medscimonit-25-8891]--[@b9-medscimonit-25-8891]\]. The best treatment of DMLs is still debated. Although arthroscopic surgery is still widely performed in the management of DMLs \[[@b10-medscimonit-25-8891]\], guidelines and research recommend against surgery due to the non-superiority of arthroscopic surgery over non-operative treatment \[[@b11-medscimonit-25-8891]--[@b13-medscimonit-25-8891]\]. Biological therapies such as platelet-rich plasma intrameniscal injection may be promising treatments for DMLs \[[@b14-medscimonit-25-8891]\]. Therefore, better understanding of biological properties and molecular mechanisms in progression of DMLs may promote development of more effective therapeutic strategies.

Recently, microarray technology, which is an effective and high-throughput molecular technique for simultaneously analyzing expression of multiple genes, has been pervasively used in a range of research areas to discover the differentially-expressed genes within molecular mechanisms, distinct pathways, and protein--protein interactions (PPI), and to reveal connections between disease and genes \[[@b15-medscimonit-25-8891]--[@b20-medscimonit-25-8891]\]. Sun et al. detected many differentially-expressed genes (DEGs) between osteoarthritic meniscal cells and normal meniscal cells \[[@b21-medscimonit-25-8891]\]. Brophy et al. found the transcripts and biological processes in OA menisci were different from non-OA menisci \[[@b22-medscimonit-25-8891]\]. Rai et al. revealed a correlation of body mass index to gene expression in ruptured menisci and a biologic association between obesity and knee osteoarthritis \[[@b23-medscimonit-25-8891]\]. Microarray analysis combined with bioinformatics provides a novel and effective method to investigate the comprehensive molecular mechanisms in meniscus injuries \[[@b24-medscimonit-25-8891]\], and may be useful to improve understanding of the connections between DEGs and DMLs.

To explore the molecular mechanisms of DMLs in OA patients, the present study aimed to identify the key DEGs and functional pathways in OA DMLs by use of comprehensive bioinformatics methods. As OA menisci have unique biological properties, we reanalyzed the gene expression profile of GSE52042, which identified the DEGs between diseased or severe degenerative tear OA menisci and healthier OA menisci. Subsequently, extensive bioinformatics analysis was carried out for gene ontology (GO) analysis, reactome pathways identification, PPI network screening, and modules extraction. The results of this work may provide further insights into the pathogenesis of OA DMLs at the molecular level and help explore potential biotherapeutic targets for it. To the best of our knowledge, there is no previously published bioinformatics analysis of this database.

Material and Methods
====================

Microarray data
---------------

The GSE52042 dataset in Gene Expression Omnibus (*[www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)*) was downloaded for subsequent analysis. GSE52042 was based on GPL17882 platform (Human MI ReadyArray™ 49K Human Genomic Array; Microarrays, Inc., Huntsville, AL, USA), including 4 diseased meniscus samples with thoroughly degraded surfaces and 4 healthier meniscus samples with integrated surfaces, which were obtained from late-stage of knee OA.

Identification of DEGs in diseased and healthier samples
--------------------------------------------------------

The DEGs between diseased and healthier samples were screened by GEO2R (*<http://www.ncbi.nlm.nih.gov/geo/geo2r/>*). *P* value \<0.05 and log fold change (FC) \<−1.0 or log FC \>1.0 were defined as the cutoff criteria. A volcano plot and a heatmap were constructed using R software (version 3.6.0).

Functional and reactome pathway analysis of DEGs
------------------------------------------------

GO enrichment analysis was carried out by the "ClusterProfiler" package of Bioconductor \[[@b25-medscimonit-25-8891]\] to assess the potential functions of DEGs in molecular function (MF), cellular component (CC), and biological process (BP). Overrepresented enriched reactome pathways were searched for using the "ReactomePA" package of Bioconductor \[[@b26-medscimonit-25-8891]\] to identify pathways that were strongly related to DEGs. The *P* value \<0.05 and false discovery rate (FDR) \<0.05 were set as the cutoff for criteria.

Construction of PPI network and modules analysis
------------------------------------------------

All DEGs were uploaded to STRING (version 11.0; *<http://string-db.org/>*) to evaluate the PPI interactive relationships among DEGs. Confidence score \>0.4 was defined as the cutoff criterion. Subsequently, the PPI network was visualized using Cytoscape software (version 3.6.1; [www.cytoscape.org](www.cytoscape.org)). The cytoHubba plugin (version 0.1) \[[@b27-medscimonit-25-8891]\] was used to extract the hub genes. Then, the modules were extracted using the Molecular Complex Detection plugin (version 1.5.1) according to the criteria: Degree Cutoff=10, Max. Depth=100, K-Core=2, Mode Score Cutoff=0.2, and MCODE score ≥4 \[[@b28-medscimonit-25-8891]\].

Results
=======

Identification of DEGs
----------------------

In comparing diseased samples to healthier samples, a total of 154 DEGs including 64 upregulated and 90 downregulated genes were identified from the GSE52042 dataset. The top 10 upregulated and downregulated DEGs are shown in [Table 1](#t1-medscimonit-25-8891){ref-type="table"}. The heatmap and volcano plot for total DEGs are illustrated in [Figures 1](#f1-medscimonit-25-8891){ref-type="fig"} and [2](#f2-medscimonit-25-8891){ref-type="fig"}, respectively.

GO terms enrichment analysis
----------------------------

In terms of BP, the upregulated DEGs were primarily participated in female pregnancy, positive regulation of cell cycle, multi-multicellular organism process, positive regulation of mitotic cell cycle, and chromosome segregation, and the downregulated DEGs were chiefly enriched in extracellular matrix (ECM) organization, extracellular structure organization, glycosaminoglycan catabolic process, aminoglycan catabolic process, and keratan sulfate catabolic process.

In terms of CC, the upregulated DEGs were mostly enriched in spindle, midbody, spindle pole, mitotic spindle, and condensed chromosome kinetochore, and the downregulated DEGs were predominantly enriched in collagen-containing extracellular matrix, extracellular matrix, lysosomal lumen, vacuolar lumen, and Golgi lumen.

In terms of MF, the upregulated DEGs were predominantly enriched in ubiquitin-like protein ligase binding. The downregulated DEGs were chiefly involved in extracellular matrix structural constituent, extracellular matrix structural constituent conferring compression resistance, growth factor binding, collagen binding, and glycosaminoglycan binding.

The top 5 BP, CC, and MF enrichment analyses of the DEGs are displayed in [Table 2](#t2-medscimonit-25-8891){ref-type="table"}. The bubble charts of the DEGs are shown in [Figures 3](#f3-medscimonit-25-8891){ref-type="fig"} and [4](#f4-medscimonit-25-8891){ref-type="fig"}, which exhibit the overview of GO terms (the top 5 BP, CC, and MF enrichment analyses). The chord diagrams of the DEGs are illustrated in [Figures 5](#f5-medscimonit-25-8891){ref-type="fig"} and [6](#f6-medscimonit-25-8891){ref-type="fig"}, which display the relationship between DEGs and GO terms (the top 5 BP, CC, and MF enrichment analyses).

Reactome pathway analysis
-------------------------

The upregulated DEGs were chiefly enriched in TP53, which regulates transcription of genes involved in G2 cell cycle arrest, condensation of prometaphase chromosomes, nuclear pore complex (NPC) disassembly, resolution of sister chromatid cohesion, and Golgi cisternae pericentriolar stack reorganization, and the downregulated DEGs were predominantly enriched in diseases associated with glycosaminoglycan metabolism, extracellular matrix organization, keratan sulfate degradation, diseases of glycosylation, and keratan sulfate biosynthesis. [Table 3](#t3-medscimonit-25-8891){ref-type="table"} lists the top 10 reactome pathways of the DEGs.

Construction of PPI network and modules analysis
------------------------------------------------

The PPI network was screened, comprising 124 nodes and 355 edges ([Figure 7](#f7-medscimonit-25-8891){ref-type="fig"}). The top 10 hub genes were identified by cytoHubba plugin using the Maximal Clique Centrality (MCC) method, including *TYMS*,*AURKA*,*CENPN*,*NUSAP1*,*CENPM*,*TPX2*,*CDK1*,*UBE2C*,*BIRC5,* and*CCNB1* ([Table 4](#t4-medscimonit-25-8891){ref-type="table"}, [Figure 8](#f8-medscimonit-25-8891){ref-type="fig"}). Among these genes, *CDK1* and *CCNB1* showed the highest node degree. Then, 2 eligible modules of the gene interaction network were screened using the Molecular Complex Detection plugin ([Figure 9](#f9-medscimonit-25-8891){ref-type="fig"}). Module 1, consisting of 14 nodes and 91 edges, had 14 scores, while module 2, including 4 nodes and 6 edges, had 4 scores. Reactome pathways analysis revealed that genes in module 1 were primarily associated with M Phase, Resolution of Sister Chromatid Cohesion, Cell Cycle Checkpoints, Mitotic Prometaphase, and Condensation of Prometaphase Chromosomes, while in module 2 they were keratan sulfate degradation, keratan sulfate biosynthesis, keratan sulfate/keratin metabolism, diseases associated with glycosaminoglycan metabolism, and extracellular matrix organization. The top 10 reactome pathways of these modules are listed in [Table 5](#t5-medscimonit-25-8891){ref-type="table"}.

Discussion
==========

OA is a disease involving the whole joint, and DMLs plays a critical role in the process of knee OA \[[@b7-medscimonit-25-8891]--[@b9-medscimonit-25-8891],[@b29-medscimonit-25-8891]--[@b31-medscimonit-25-8891]\]. However, the treatment of DMLs remains a conundrum. Meniscectomy has no benefit over non-operative treatments, while non-operative measures such as nonsteroidal anti-inflammatory drugs, exercise therapy, and rest are the mainstay of management for DMLs \[[@b32-medscimonit-25-8891]\]. Therefore, better understanding of the underlying pathogenesis of DMLs is of pivotal importance for identification of therapeutic targets and may drive future studies to search for biological treatments of this disease. The high-throughput microarray technology combined with bioinformatics analysis has been widely used in various diseases to predict potential molecular therapeutic targets. In the present study, the microarray dataset GSE52042, comprising healthier and diseased meniscus samples, was obtained, and a bioinformatics analysis was completed. A total of 154 DEGs were identified, including 64 upregulated and 90 downregulated DEGs. Furthermore, in order to probe into the biological significances behind these DEGs, GO, Reactome pathway, and PPI analysis were performed.

In view of the results of GO terms enrichment analysis, we linked the downregulated DEGs with ECM organization, collagen-containing ECM, and ECM structural constituent, and observed the upregulated DEGs had a close relationship with positive regulation of mitotic cell cycle, spindle, and ubiquitin-like protein ligase binding. The meniscus ECM, which plays a crucial role in sustaining structural integrity and mechanical properties of meniscus, is primarily composed of water, collagen, proteoglycan, glycoprotein, elastin, and linking protein \[[@b33-medscimonit-25-8891],[@b34-medscimonit-25-8891]\]. Histopathological analysis showed that degenerated menisci could result in a loss of ECM structure \[[@b35-medscimonit-25-8891]\]. Herwig et al. demonstrated that the collagen and glycosaminoglycan contents (chondroitin 4-sulphate, dermatan sulphate, and keratan sulphate) declined with increasing meniscus degeneration \[[@b36-medscimonit-25-8891]\]. Meniscus cells are composed by different cell types, which possess proliferation ability and hasten meniscus repair \[[@b37-medscimonit-25-8891]--[@b41-medscimonit-25-8891]\]. Positive regulation of mitotic cell cycle can result in cell proliferation \[[@b42-medscimonit-25-8891]\]. Nishida et al. observed fibroblasts and fibrochondrocyte-like cells proliferated but glycosaminoglycans and the cell count decreased remarkably after experimental dog meniscus tearing, indicating that ECM disorder and cell proliferation could coexist in the degenerative meniscus tear \[[@b43-medscimonit-25-8891]\]. Lopez-Franco et al. showed that decreased proteoglycan, cartilage oligomeric matrix protein, and cell population altered the ECM organization in degenerative menisci, and actively dividing cells were found in all recently injured menisci samples and in 1 degenerative menisci sample \[[@b44-medscimonit-25-8891]\].

The downregulated DEGs reactome pathways were predominantly involved in diseases associated with glycosaminoglycan metabolism, extracellular matrix organization, keratan sulfate degradation, diseases of glycosylation, and keratan sulfate biosynthesis. These results indicated the disorder of ECM was present in DMLs. Reactome pathway analysis of the upregulated DEGs were predominantly enriched in TP53, which regulates transcription of genes involved in G2 cell cycle arrest, condensation of prometaphase chromosomes, nuclear pore complex (NPC) disassembly, resolution of sister chromatid cohesion, and Golgi cisternae pericentriolar stack reorganization, and these were related to cell proliferation, consistent with the results of GO terms enrichment analysis of upregulated DEGs.

The PPI network was screened to predict the connections of protein functions of DEGs, and the top 10 hub genes -- *TYMS*,*AURKA*,*CENPN*,*NUSAP1*,*CENPM*,*TPX2*,*CDK1*,*UBE2C*, *BIRC5,* and *CCNB1 --* were presented. Some hub genes are closely associated with osteoarthritic chondrocytes. Cyclin-dependent kinase 1 (CDK1), a highly conserved small protein, is a member of the cyclin-dependent kinase family that serves as a serine/threonine kinase and the catalytic subunit of mitosis-phase promoting factor, playing a pivotal role in controlling cell cycle, such as mitotic onset and driving G2-M transition \[[@b45-medscimonit-25-8891]--[@b49-medscimonit-25-8891]\]. CDK1 was detected in human and rat osteoarthritic chondrocytes \[[@b50-medscimonit-25-8891]\]. Saito et al. demonstrated that overexpression of CDK1 could cause chondrocyte proliferation, and its low expression could result in chondrocyte differentiation and maturity, indicating CDK1 was essential for chondrocytes proliferation and differentiation \[[@b51-medscimonit-25-8891]\]. Cyclin B1 (CCNB1) is one of cell cycle proteins which are essential regulators of cell division, and complexes with CDK1 to form a mitosis-phase-promoting factor that promotes mitosis \[[@b46-medscimonit-25-8891],[@b47-medscimonit-25-8891]\]. Zhou et al. found that platelets could upregulate the proliferation of rat osteoarthritic chondrocytes via stimulation of the ERK/CDK1/CCNB1 pathway \[[@b52-medscimonit-25-8891]\]. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also called survivin, is a protein that belongs to the inhibitor of apoptosis family, which localizes to the spindle, expressed in the G2/M phase, and plays a key role in the regulation of mitosis and protection of cells from apoptosis \[[@b53-medscimonit-25-8891],[@b54-medscimonit-25-8891]\]. BIRC5 was detected in human osteoarthritic chondrocytes, and its suppression expression can lead to reduced rates of chondrocyte proliferation and G2/M blockade \[[@b55-medscimonit-25-8891]\]. Aurora kinase A (AURKA) is a type of Aurora kinase and is crucial for the successful execution of mitosis \[[@b56-medscimonit-25-8891]\]. AURKA was highly expressed in human osteoarthritic chondrocytes and overexpression of AURKA could contributes to the development of knee osteoarthritis \[[@b57-medscimonit-25-8891]\]. In the present study, AURKA, CDK1, BIRC5, and CCNB1 were upregulated in diseased menisci compared to healthier menisci in late-stage knee OA, indicating diseased meniscus cells tended to cell proliferation.

Two modules were extracted from the PPI network. Most of the genes presented in module 1 are the aforementioned hub genes. The genes in module 2 relate to ECM metabolism. Matrix metalloproteinase-2 (MMP2) is a matrix metalloproteinase with ECM-degrading components \[[@b58-medscimonit-25-8891]\]. Stone observed that late-stage OA meniscus cell cultures secreted more MMP2 than normal meniscus cell cultures when stimulated by pro-inflammatory factors \[[@b59-medscimonit-25-8891]\]. Cook et al. found that when stimulated by interleukin-1β, MMP2 expression was decreased, but other matrix metalloproteinases were increased in canine meniscus cell cultures \[[@b60-medscimonit-25-8891]\]. James et al. found that co-culture of meniscus and the infrapatellar fat pad, which is a major sources of pro-inflammatory factors, increased sulfated glycosaminoglycan degeneration but decreased MMP2 production \[[@b61-medscimonit-25-8891]\]. In the present study, MMP2 was downregulated in diseased menisci compared to healthier menisci. Lumican (LUM) and fibromodulin (FMOD) are Class II small leucine-rich proteoglycans and are components of tendon and cartilage, with effects on collagen fibril structure and tissue stiffness \[[@b62-medscimonit-25-8891],[@b63-medscimonit-25-8891]\]. Önnerfjord et al. found that LUM and FMOD were highly expressed in menisci, and the relative content between them in different tissues was negatively correlated \[[@b64-medscimonit-25-8891]\]. Melrose et al. found that the expression of LUM and FMOD in menisci were consistent in late-stage knees OA versus age-matched normal knee joints \[[@b65-medscimonit-25-8891]\]. Endo et al. observed that LUM was upregulated in menisci in early-phase knee OA \[[@b66-medscimonit-25-8891]\]. Hellio observed that the FMOD expression was downregulated in the lateral meniscus at 3 weeks after anterior cruciate ligament transection for experimental OA in rabbits, but returned to normal at 8 weeks after surgery \[[@b67-medscimonit-25-8891]\]. Aggrecan (ACAN) is a macromolecular proteoglycan and a crucial component of meniscus ECM, helping to maintain biomechanical properties of ECM \[[@b68-medscimonit-25-8891]--[@b71-medscimonit-25-8891]\]. Favero et al. found that OA meniscus and synovium could release inflammatory molecules to induce meniscus ACAN degradation and ECM loss \[[@b72-medscimonit-25-8891]\]. Freymann et al. observed that human serum could stimulate meniscal cells obtained from advanced degenerative menisci in end-stage OA patients to express aggrecan \[[@b73-medscimonit-25-8891]\]. In the present study, LUM, FMOD, and ACAN were downregulated in diseased menisci compared to healthier menisci in late-stage knee OA, indicating the ECM structure was impaired in diseased menisci.

According to the present results, some of the genes promoting cell proliferation were upregulated, while some of the genes constituting meniscus ECM were downregulated in the diseased meniscus samples, indicating that cell repair and ECM degradation may coexist in the process of osteoarthritic DMLs, which reflected the disorder of cell proliferation and the impairment of ECM integrality in osteoarthritic DMLs. Better understanding of these unique biological features may help develop potential therapies for osteoarthritic DMLs.

Conclusions
===========

We conducted a comprehensive bioinformatics analysis on gene expression profile of OA meniscus. Key genes and pathways were identified to provide more detailed molecular mechanisms for the process of osteoarthritic DMLs and shed light on potential therapeutic targets. Nevertheless, further experiments are needed to further validate the identified genes and pathways.

**Conflicts of interest**

None.

**Source of support:** The present study was supported by the Zhejiang Chinese Medicine Technology Project (grant no. 2018ZB140) and the Medical and Health Science and Technology Plan Project of Zhejiang Province (grant no. 2017KY725).

![Heat map plot of total DEGs.](medscimonit-25-8891-g001){#f1-medscimonit-25-8891}

![Volcano plot of total DEGs.](medscimonit-25-8891-g002){#f2-medscimonit-25-8891}

![Bubble chart of upregulated DEGs.](medscimonit-25-8891-g003){#f3-medscimonit-25-8891}

![Bubble chart of downregulated DEGs.](medscimonit-25-8891-g004){#f4-medscimonit-25-8891}

![Chord diagram of upregulated DEGs.](medscimonit-25-8891-g005){#f5-medscimonit-25-8891}

![Chord diagram of downregulated DEGs.](medscimonit-25-8891-g006){#f6-medscimonit-25-8891}

![PPI network of DEGs.](medscimonit-25-8891-g007){#f7-medscimonit-25-8891}

![The top 10 hub genes.](medscimonit-25-8891-g008){#f8-medscimonit-25-8891}

![(**A, B**) Two modules.](medscimonit-25-8891-g009){#f9-medscimonit-25-8891}

###### 

The top 10 upregulated and downregulated DEGs.

                  Gene symbol   logFC      P value
  --------------- ------------- ---------- ----------
  Downregulated   *FMOD*        −2.396     0.000533
  *MXRA5*         −2.255        0.021918   
  *VCAM1*         −1.923        0.000582   
  *LRP1*          −1.922        0.011987   
  *CFH*           −1.879        0.002062   
  *TIMP2*         −1.878        5.67E-05   
  *OAS1*          −1.844        0.000157   
  *CSPG4*         −1.835        0.000205   
  *LTBP3*         −1.804        0.002253   
  *THBS2*         −1.726        0.007495   
  Upregulated     *PSG9*        2.081      0.003259
  *PSG4*          1.927         0.003893   
  *PSG11*         1.836         0.004486   
  *FSTL1*         1.776         0.001282   
  *PSG8*          1.774         0.000716   
  *EGR1*          1.739         9.56E-05   
  *FOS*           1.732         0.000996   
  *NEK7*          1.728         0.015207   
  *ACTR2*         1.683         0.004529   
  *KRT18P21*      1.608         7.42E-06   

###### 

The top 5 BP, CC, and MF enrichment analyses of the upregulated and downregulated DEGs.

  Ontology            GO ID         Description                                                                     Count   Gene ratio   P value    Adjust p value   FDR
  ------------------- ------------- ------------------------------------------------------------------------------- ------- ------------ ---------- ---------------- ----------
  **Downregulated**                                                                                                                                                  
  BP                  GO: 0030198   Extracellular matrix organization                                               18      0.22         9.33E-15   2.08E-11         1.57E-11
  BP                  GO: 0043062   Extracellular structure organization                                            18      0.22         1.18E-13   1.31E-10         9.87E-11
  BP                  GO: 0006027   Glycosaminoglycan catabolic process                                             8       0.10         3.29E-10   2.39E-07         1.80E-07
  BP                  GO: 0006026   Aminoglycan catabolic process                                                   8       0.10         4.29E-10   2.39E-07         1.80E-07
  BP                  GO: 0042340   Keratan sulfate catabolic process                                               5       0.06         1.37E-09   4.85E-07         3.66E-07
  CC                  GO: 0062023   Collagen-containing extracellular matrix                                        24      0.30         1.59E-21   2.83E-19         2.17E-19
  CC                  GO: 0031012   Extracellular matrix                                                            24      0.30         6.65E-20   5.92E-18         4.55E-18
  CC                  GO: 0043202   Lysosomal lumen                                                                 10      0.13         6.91E-12   4.10E-10         3.15E-10
  CC                  GO: 0005775   Vacuolar lumen                                                                  11      0.14         1.45E-10   6.43E-09         4.95E-09
  CC                  GO: 0005796   Golgi lumen                                                                     8       0.10         1.13E-08   4.04E-07         3.10E-07
  MF                  GO: 0005201   Extracellular matrix structural constituent                                     15      0.19         6.88E-16   1.64E-13         1.36E-13
  MF                  GO: 0030021   Extracellular matrix structural constituent conferring compression resistance   5       0.06         3.94E-08   4.68E-06         3.89E-06
  MF                  GO: 0019838   Growth factor binding                                                           7       0.09         1.63E-06   0.000129         0.000107
  MF                  GO: 0005518   Collagen binding                                                                4       0.05         0.000195   0.011595         0.009641
  MF                  GO: 0005539   Glycosaminoglycan binding                                                       6       0.08         0.000353   0.016785         0.013956
  **Upregulated**                                                                                                                                                    
  BP                  GO: 0007565   Female pregnancy                                                                8       0.14         1.43E-07   0.000172         0.000127
  BP                  GO: 0045787   Positive regulation of cell cycle                                               10      0.18         2.06E-07   0.000172         0.000127
  BP                  GO: 0044706   Multi-multicellular organism process                                            8       0.14         4.63E-07   0.000206         0.000151
  BP                  GO: 0045931   Positive regulation of mitotic cell cycle                                       7       0.13         4.93E-07   0.000206         0.000151
  BP                  GO: 0007059   Chromosome segregation                                                          8       0.14         2.09E-06   0.000699         0.000513
  CC                  GO: 0005819   Spindle                                                                         8       0.14         7.09E-06   0.001305         0.001105
  CC                  GO: 0030496   Midbody                                                                         6       0.10         1.47E-05   0.001354         0.001146
  CC                  GO: 0000922   Spindle pole                                                                    5       0.09         0.000108   0.006634         0.005617
  CC                  GO: 0072686   Mitotic spindle                                                                 4       0.07         0.000234   0.009674         0.008191
  CC                  GO: 0000777   Condensed chromosome kinetochore                                                4       0.07         0.000263   0.009674         0.008191
  MF                  GO: 0044389   Ubiquitin-like protein ligase binding                                           6       0.12         0.000207   0.038328         0.031622

###### 

The top 10 significantly enriched reactome pathways of the upregulated and downregulated DEGs.

  Reactome ID         Description                                                              Count   P value    FDR        Gene symbol
  ------------------- ------------------------------------------------------------------------ ------- ---------- ---------- -------------------------------------------------------------------------------------------------------
  **Downregulated**                                                                                                          
  R-HSA-3560782       Diseases associated with glycosaminoglycan metabolism                    8       6.07E-11   1.10E-08   *FMOD, CSPG4, ACAN, LUM, PRELP, GPC1, OGN, BCAN*
  R-HSA-1474244       Extracellular matrix organization                                        15      9.43E-11   1.10E-08   *FMOD, VCAM1, TIMP2, LTBP3, ITGB2, COL8A2, ACAN, FBLN1, LUM, PLEC, LAMB2, COL12A1, BCAN, MMP2, LTBP2*
  R-HSA-2022857       Keratan sulfate degradation                                              5       6.58E-09   5.10E-07   *FMOD, ACAN, LUM, PRELP, OGN*
  R-HSA-3781865       Diseases of glycosylation                                                9       1.08E-07   6.29E-06   *FMOD, CSPG4, THBS2, ACAN, LUM, PRELP, GPC1, OGN, BCAN*
  R-HSA-2022854       Keratan sulfate biosynthesis                                             5       4.70E-07   1.87E-05   *FMOD, ACAN, LUM, PRELP, OGN*
  R-HSA-1630316       Glycosaminoglycan metabolism                                             8       4.83E-07   1.87E-05   *FMOD, CSPG4, ACAN, LUM, PRELP, GPC1, OGN, BCAN*
  R-HSA-1638074       Keratan sulfate/keratin metabolism                                       5       1.30E-06   4.31E-05   *FMOD, ACAN, LUM, PRELP, OGN*
  R-HSA-71387         Metabolism of carbohydrates                                              10      6.05E-06   0.000176   *FMOD, CSPG4, ACAN, LUM, PRELP, GPC1, OGN, BCAN, PYGB, MAN2B1*
  R-HSA-3000178       ECM proteoglycans                                                        5       7.15E-05   0.001849   *FMOD, ACAN, LUM, LAMB2, BCAN*
  R-HSA-1474228       Degradation of the extracellular matrix                                  6       0.000144   0.003091   *TIMP2, COL8A2, ACAN, COL12A1, BCAN, MMP2*
  **Upregulated**                                                                                                            
  R-HSA-6804114       TP53 regulates transcription of genes involved in G2 cell cycle arrest   4       1.37E-06   0.000294   *AURKA, CDK1, BAX, CCNB1*
  R-HSA-2514853       Condensation of prometaphase chromosomes                                 3       1.68E-05   0.001539   *CDK1, CCNB2, CCNB1*
  R-HSA-3301854       Nuclear pore complex (NPC) disassembly                                   4       2.21E-05   0.001539   *CDK1, CCNB2, CCNB1, NEK7*
  R-HSA-2500257       Resolution of sister chromatid cohesion                                  6       2.88E-05   0.001539   *CDK1, CENPM, CCNB2, CENPN, CCNB1, BIRC5*
  R-HSA-162658        Golgi cisternae pericentriolar stack reorganization                      3       3.66E-05   0.001564   *CDK1, CCNB2, CCNB1*
  R-HSA-202733        Cell surface interactions at the vascular wall                           6       4.62E-05   0.001645   *PSG7, PSG3, PSG8, PSG11, PSG4, PSG9*
  R-HSA-6791312       TP53 regulates transcription of cell cycle genes                         4       8.53E-05   0.002274   *AURKA, CDK1, BAX, CCNB1*
  R-HSA-68886         M phase                                                                  9       9.46E-05   0.002274   *CDK1, CENPM, KIF20A, CCNB2, CENPN, UBE2C, CCNB1, BIRC5, NEK7*
  R-HSA-176412        Phosphorylation of the APC/C                                             3       9.58E-05   0.002274   *CDK1, UBE2C, CCNB1*
  R-HSA-2980766       Nuclear envelope breakdown                                               4       0.000108   0.002303   *CDK1, CCNB2, CCNB1, NEK7*

###### 

The top 10 hub genes.

  Gene symbol   Degree   MCC
  ------------- -------- ----------
  CDK1          21       6.23E+09
  CCNB1         21       6.23E+09
  AURKA         18       6.23E+09
  TPX2          15       6.23E+09
  UBE2C         15       6.23E+09
  CENPM         14       6.23E+09
  CENPN         14       6.23E+09
  NUSAP1        14       6.23E+09
  BIRC5         14       6.23E+09
  TYMS          14       6.23E+09

###### 

The top 10 significantly enriched reactome pathways of module 1 and 2.

  Reactome ID     Description                                                              Count   P value    FDR         Gene symbol
  --------------- ------------------------------------------------------------------------ ------- ---------- ----------- ----------------------------------------------------------
  **Module 1**                                                                                                            
  R-HSA-68886     M Phase                                                                  8       1.48E-09   4.09E-08    *CDK1, UBE2C, CCNB1, CCNB2, BIRC5, KIF20A, CENPN, CENPM*
  R-HSA-2500257   Resolution of sister chromatid cohesion                                  6       2.16E-09   4.09E-08    *CDK1, CCNB1, CCNB2, BIRC5, CENPN, CENPM*
  R-HSA-69620     Cell cycle checkpoints                                                   7       7.98E-09   1.01E-07    *CDK1, UBE2C, CCNB1, CCNB2, BIRC5, CENPN, CENPM*
  R-HSA-68877     Mitotic prometaphase                                                     6       3.48E-08   3.30E-07    *CDK1, CCNB1, CCNB2, BIRC5, CENPN, CENPM*
  R-HSA-2514853   Condensation of prometaphase chromosomes                                 3       1.81E-07   1.37E-06    *CDK1, CCNB1, CCNB2*
  R-HSA-162658    Golgi cisternae pericentriolar stack reorganization                      3       3.99E-07   2.52E-06    *CDK1, CCNB1, CCNB2*
  R-HSA-6804114   TP53 regulates transcription of genes involved in G2 cell cycle arrest   3       8.91E-07   4.82E-06    *CDK1, CCNB1, AURKA*
  R-HSA-176412    Phosphorylation of the APC/C                                             3       1.06E-06   5.01E-06    *CDK1, UBE2C, CCNB1*
  R-HSA-69275     G2/M transition                                                          5       1.45E-06   5.61E-06    *CDK1, CCNB1, CCNB2, AURKA, TPX2*
  R-HSA-453274    Mitotic G2-G2/M phases                                                   5       1.53E-06   5.61E-06    *CDK1, CCNB1, CCNB2, AURKA, TPX2*
  **Module 2**                                                                                                            
  R-HSA-2022857   Keratan sulfate degradation                                              3       5.73E-09   1.81E-08    *ACAN, FMOD, LUM*
  R-HSA-2022854   Keratan sulfate biosynthesis                                             3       6.56E-08   1.04E-07    *ACAN, FMOD, LUM*
  R-HSA-1638074   Keratan sulfate/keratin metabolism                                       3       1.20E-07   1.26E-07    *ACAN, FMOD, LUM*
  R-HSA-3560782   Diseases associated with glycosaminoglycan metabolism                    3       2.13E-07   1.68E-07    *ACAN, FMOD, LUM*
  R-HSA-1474244   Extracellular matrix organization                                        4       6.33E-07   4.00E-07    *ACAN, FMOD, MMP2, LUM*
  R-HSA-3000178   ECM proteoglycans                                                        3       1.40E-06   7.38E-07    *ACAN, FMOD, LUM*
  R-HSA-1630316   Glycosaminoglycan metabolism                                             3       6.16E-06   2.78E-06    *ACAN, FMOD, LUM*
  R-HSA-3781865   Diseases of glycosylation                                                3       9.47E-06   3.74E-06    *ACAN, FMOD, LUM*
  R-HSA-71387     Metabolism of carbohydrates                                              3       8.32E-05   2.92E-05    *ACAN, FMOD, LUM*
  R-HSA-1474228   Degradation of the extracellular matrix                                  2       0.001018   0.0003214   *ACAN, MMP2*

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
